AVNR Stock News 4.76 05/13/2014 17:57:47 Avanir Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Avanir Pharmaceuticals Inc (AVNR) 4.76 $AVNR

Avanir Loss In Line with Ests, Revs Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 4:00PM CDT
Avanir Pharma (AVNR) reported second quarter fiscal 2014 net loss per share of 8 cents, in line with the Zacks Consensus Estimate.

Avanir's Loss Narrows as Nuedexta Revenue Rises
Sean Williams, The Motley Fool - Motley Fool - Tue May 06, 4:21PM CDT
Small-cap biopharmaceutical company Avanir Pharmaceuticals continued to showcase its progress to investors today by reporting greatly improved sales and a narrower loss with the release of its second-quarter results after the closing bell. For...

Avanir Pharmaceuticals Reports Fiscal 2014 Second Quarter Financial and Business Results
PR Newswire - Tue May 06, 3:01PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2014.

Trade-Ideas: AVANIR Pharmaceuticals (AVNR) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri May 02, 8:45AM CDT
Trade-Ideas LLC identified AVANIR Pharmaceuticals (AVNR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Upgrade Alert for AVANIR Pharmaceuticals (AVNR)
Comtex SmarTrend(R) - Fri May 02, 7:03AM CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $4.65 on volume of 11.7 million shares, above average daily volume of 2.0 million. AVANIR Pharmaceuticals Inc. develops, acquires, and markets treatments for central nervous system disorders, inflammation, and infectious diseases.

Avanir Wins Lawsuit, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 3:39PM CDT
Shares of Avanir (AVNR) soared 45.6% after the the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit in its favor.

Avanir Pharmaceuticals (AVNR) Stock Falls Off After Yesterday's Gain
at The Street - Thu May 01, 3:08PM CDT
Avanir Pharmaceuticals (AVNR) spiked Wednesday afternoon after a court ruled in the company's favor in a patent litigation case, but the shares had fallen off considerably by the close of trading Thursday.

Avanir Pharmaceuticals to Participate in Two Conferences in May
PR Newswire - Thu May 01, 3:00PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in May.

Stock to Watch: AVANIR Pharmaceuticals Down 5.0% (AVNR)
Comtex SmarTrend(R) - Thu May 01, 10:40AM CDT
AVANIR Pharmaceuticals (NASDAQ:AVNR) is one of today's worst performing low-priced stocks, down 5.0% to $4.73 on 3.7x average daily volume. Thus far today, AVANIR Pharmaceuticals has traded 7.3 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-5.0% to the Dow's -0.0%) and underperformed the S&P 500 (-5.0% to the S&P's 0.1%) during today's trading.

Pre-Market Scans on Top Gainers -- Research on NQ Mobile, AVANIR Pharma, WellPoint, and Aspen Technology
PR Newswire - Thu May 01, 7:50AM CDT
The US markets saw a positive sentiment on Wednesday, April 30, 2014, with the NASDAQ Composite closing at 4,114.56, up 0.27%, the Dow Jones Industrial Average ending the session 0.27% higher at 16,580.84, and the S&P 500 edging 0.30% higher to finish the trading session at 1,883.95. The recent session welcomed some action on the Materials, Industrials, and Consumer Discretionary sectors that positively impacted the broader market. A number of stocks saw large movements, including NQ Mobile Inc. (NYSE: NQ), AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), WellPoint Inc. (NYSE: WLP) and Aspen Technology Inc. (NASDAQ: AZPN). Free technical research on NQ, AVNR, WLP and AZPN can be downloaded upon signing up at:

Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.

Fed Shows Confidence in Market with Cut in Bond Buying Stimulus
PR Newswire Europe - Thu May 01, 6:33AM CDT
LONDON, May 1, 2014 /PRNewswire/ --

Why Avanir Pharmaceuticals, Pepco, and Level 3 Communications Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 4:15PM CDT
I hope you're a good swimmer, because we were absolutely buried with economic data on this last day of April. The end result was a whipsaw effect in the broad-based S&P 500 , which left it modestly higher for the session. We started the...

Why Avanir Pharmaceuticals (AVNR) Stock Spiked Today
at The Street - Wed Apr 30, 2:21PM CDT
Avanir Pharmaceuticals (AVNR) spiked Wednesday afternoon after the U.S. District Court for the District of Delaware ruled in the company's favor in its patent infringement lawsuit against Par Pharmaceuticals and Impax Laboratories over NUEDEXTA.

Avanir Pharmaceuticals Prevails in NUEDEXTA Patent Trial Resulting in Exclusivity Through 2026
PR Newswire - Wed Apr 30, 2:04PM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Avanir in the company's patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications ('ANDAs' for generic versions of NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect.

Avanir Pharmaceuticals Announces Date of Fiscal 2014 Second Quarter Financial Results and Conference Call
GlobeNewswire - Tue Apr 29, 9:29AM CDT
Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) will report financial results for the quarter ended March 31, 2014 after market close on Tuesday May 6, 2014. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.

Avanir Pharmaceuticals Announces Multiple Data Presentations Highlighting Its Central Nervous System (CNS) Therapeutics Franchise at the 66th Annual Meeting of the American Academy of Neurology
PR Newswire - Mon Apr 28, 7:30AM CDT
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology, discussing PBA diagnosis in patients with Alzheimer's disease (AD) and other dementias, will be available at AAN and was recently published online. The AAN presentations and US Neurology publication offer important new insights into the prevalence, diagnosis, impact and treatment of PBA, a distressing neurological condition characterized by uncontrollable laughing or crying. Data from the pivotal phase III trial of AVP-825, an investigational drug-device combination product for the acute treatment of migraine will also be presented.

Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
PR Newswire - Thu Apr 10, 11:31AM CDT
The trading session on Wednesday, April 09, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 16,437.18, up 1.11% and the NASDAQ Composite closed at 4,183.90, up 1.72%. The S&P 500 finished the session 1.09% higher at 1,872.18. The gains were broad based as eight out of ten sectors posted gains. The S&P 500 Health Care Sector Index finished the day 2.11% higher at 673.27, and the same has gained 2.86% in the previous three months. Investor-Edge has initiated coverage on the following equities: Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Salix Pharmaceuticals Ltd (NASDAQ: SLXP) and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free technical research on AVNR, ZTS, SLXP and JAZZ can be downloaded upon signing up at:

Avanir's AVP-825 under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 4:20PM CDT
Avanir Pharmaceuticals announced that the New Drug Application for its migraine candidate, AVP-825, has been accepted by FDA.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 48

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 164

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 38

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 37

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 71

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

MPE Partners Invests in SKB Cases to Enhance Growth Potential

Updated Category News Views 369

MPE Partners Makes Strategic Investment in SKB Cases MPE Partners, also known as Morgenthaler Private Equity, has announced an exciting investment in SKB Cases, a prominent manufacturer known for its specialty protective cases. With a robust customer base exceeding 2,000 clients across military, industrial, music, and pro AV sectors, this strategic move is set to...

Continue Reading
Aspire Expands into Europe with EU EMI License and Hub Establishment

Updated Category News Views 186

Aspire Expands into Europe with EU EMI License Aspire, a leading global fintech firm based in Singapore, recently announced a significant breakthrough by acquiring its Electronic Money Institution (EMI) license. This important approval lays the groundwork for its operations in the Netherlands, marking the company's formal entry into the European Union. Milestone for...

Continue Reading
GOTS Combats Greenwashing with Consumer Education Campaign

Updated Category News Views 128

GOTS Takes Action Against Greenwashing The Global Organic Textile Standard (GOTS) is excited to announce the return of its #BehindTheSeams campaign, which aims to raise awareness about the sustainable features of GOTS-certified products. This year's campaign will run throughout September, expanding its efforts to educate consumers about the sustainable practices behind...

Continue Reading
Advancements in Cancer Treatment: Insights from Indaptus Therapeutics

Updated Category News Views 123

Exciting Clinical Developments by Indaptus Therapeutics Indaptus Therapeutics, Inc. (Nasdaq: INDP) is making significant strides in the realm of cancer therapy, focusing on innovative treatments for complex conditions such as urothelial cancer. Their ongoing clinical trial, labeled INDP-D101, has revealed promising results regarding their Decoy20 monotherapy. Recently, a...

Continue Reading
Dr. Réjean Boivin Appointed as Editor-in-Chief of Journal

Updated Category News Views 474

Dr. Réjean Boivin Takes the Helm at Review of Scientific Instruments AIP Publishing is excited to welcome Dr. Réjean Boivin as the new editor-in-chief for Review of Scientific Instruments. Boivin, who previously directed the Center of Excellence for Advanced Diagnostics at General Atomics, is a well-respected figure in the field, having held various roles such as...

Continue Reading